HC Wainwright Reiterates "Buy" Rating for Voyager Therapeutics (NASDAQ:VYGR)

HC Wainwright restated their buy rating on shares of Voyager Therapeutics (NASDAQ:VYGR - Free Report) in a research report released on Monday morning,Benzinga reports. They currently have a $30.00 target price on the stock.

A number of other equities research analysts also recently issued reports on VYGR. Cantor Fitzgerald started coverage on shares of Voyager Therapeutics in a research report on Friday, January 10th. They issued an "overweight" rating and a $5.73 target price for the company. Leerink Partners started coverage on Voyager Therapeutics in a research note on Wednesday, October 16th. They set an "outperform" rating and a $15.00 price target for the company. Citigroup initiated coverage on shares of Voyager Therapeutics in a research report on Monday, December 2nd. They issued a "buy" rating and a $12.00 target price for the company. StockNews.com downgraded shares of Voyager Therapeutics from a "buy" rating to a "hold" rating in a report on Friday, December 13th. Finally, Leerink Partnrs upgraded shares of Voyager Therapeutics to a "strong-buy" rating in a report on Wednesday, October 16th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $15.97.

Voyager Therapeutics Price Performance

Voyager Therapeutics stock traded down $0.02 during midday trading on Monday, reaching $5.61. The stock had a trading volume of 312,710 shares, compared to its average volume of 364,289. The firm's fifty day simple moving average is $5.80 and its two-hundred day simple moving average is $6.62. Voyager Therapeutics has a twelve month low of $4.99 and a twelve month high of $10.66. The firm has a market cap of $306.20 million, a price-to-earnings ratio of 7.91 and a beta of 0.93.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, beating analysts' consensus estimates of ($0.45) by $0.29. The business had revenue of $24.63 million for the quarter, compared to the consensus estimate of $12.63 million. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. During the same quarter in the previous year, the company posted ($0.59) earnings per share. As a group, sell-side analysts predict that Voyager Therapeutics will post -0.91 EPS for the current fiscal year.

Insider Transactions at Voyager Therapeutics

In other news, COO Robin Swartz sold 6,500 shares of the firm's stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $5.65, for a total value of $36,725.00. Following the sale, the chief operating officer now owns 112,328 shares in the company, valued at approximately $634,653.20. This trade represents a 5.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last ninety days, insiders have sold 10,778 shares of company stock worth $58,548. Company insiders own 4.53% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Hsbc Holdings PLC acquired a new stake in Voyager Therapeutics during the second quarter worth about $128,000. The Manufacturers Life Insurance Company lifted its position in shares of Voyager Therapeutics by 6.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 94,398 shares of the company's stock worth $747,000 after acquiring an additional 5,365 shares during the period. Hunter Perkins Capital Management LLC grew its holdings in shares of Voyager Therapeutics by 3.3% during the 3rd quarter. Hunter Perkins Capital Management LLC now owns 64,040 shares of the company's stock worth $375,000 after purchasing an additional 2,025 shares in the last quarter. Patriot Financial Group Insurance Agency LLC increased its position in shares of Voyager Therapeutics by 7.0% during the third quarter. Patriot Financial Group Insurance Agency LLC now owns 136,894 shares of the company's stock valued at $801,000 after purchasing an additional 9,000 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its stake in shares of Voyager Therapeutics by 64.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company's stock valued at $61,000 after purchasing an additional 4,098 shares in the last quarter. Institutional investors own 48.03% of the company's stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.